{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T23:30:44Z","timestamp":1792625444332,"version":"4.5.0"},"reference-count":90,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.ctrv.2025.102907","type":"journal-article","created":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T03:06:55Z","timestamp":1740625615000},"page":"102907","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Functioning neuroendocrine tumors (NET): Minimum requirements for a NET specialist"],"prefix":"10.1016","volume":"135","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3642-0798","authenticated-orcid":false,"given":"F.","family":"Spada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.E.","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Modica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Gelsomino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Rinzivillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Rubino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Pisa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"La Salvia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6869-0704","authenticated-orcid":false,"given":"N.","family":"Fazio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ctrv.2025.102907_b0005","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s11912-021-01029-7","article-title":"Epidemiology, incidence, and prevalence of neuroendocrine neoplasms: are there global differences?","volume":"23","author":"Das","year":"2021","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.ctrv.2025.102907_b0010","doi-asserted-by":"crossref","unstructured":"Modica R, Liccardi A, Minotta R, Cannavale G, Benevento E, Colao A. Current understanding of pathogenetic mechanisms in neuroendocrine neoplasms. Expert Rev Endocrinol Metab. 2024 Jan-May;19(1):49-61. doi: 10.1080\/17446651.2023.2279540. Epub 2024 Jan 1. PMID: 37936421.","DOI":"10.1080\/17446651.2023.2279540"},{"key":"10.1016\/j.ctrv.2025.102907_b0015","doi-asserted-by":"crossref","unstructured":"Ruggeri RM, Benevento E, De Cicco F, Fazzalari B, Guadagno E, Hasballa I, et al. NIKE Group. Neuroendocrine neoplasms in the context of inherited tumor syndromes: a reappraisal focused on targeted therapies. J Endocrinol Invest. 2023 Feb;46(2):213-234. doi: 10.1007\/s40618-022-01905-4. Epub 2022 Aug 30. Erratum in: J Endocrinol Invest. 2023 Jan;46(1):203. doi: 10.1007\/s40618-022-01924-1. PMID: 36038743.","DOI":"10.1007\/s40618-022-01905-4"},{"issue":"5","key":"10.1016\/j.ctrv.2025.102907_b0020","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1080\/17446651.2022.2099840","article-title":"Therapeutic strategies for patients with neuroendocrine neoplasms: current perspectives","volume":"17","author":"Modica","year":"2022","journal-title":"Expert Rev Endocrinol Metab"},{"key":"10.1016\/j.ctrv.2025.102907_b0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102560","article-title":"Targeting neuroendocrine tumors with octreotide and lanreotide: Key points for clinical practice from NET specialists","volume":"117","author":"La Salvia","year":"2023","journal-title":"Cancer Treat Rev"},{"issue":"10","key":"10.1016\/j.ctrv.2025.102907_b0030","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1080\/14740338.2017.1354984","article-title":"The safety of available treatments options for neuroendocrine tumors","volume":"16","author":"Faggiano","year":"2017","journal-title":"Expert Opin Drug Saf"},{"issue":"1","key":"10.1016\/j.ctrv.2025.102907_b0035","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1186\/s12967-022-03511-7","article-title":"Identification of functional pathways and molecular signatures in neuroendocrine neoplasms by multi-omics analysis","volume":"20","author":"Melone","year":"2022","journal-title":"J Transl Med"},{"issue":"1","key":"10.1016\/j.ctrv.2025.102907_b0040","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/MED.0000000000000376","article-title":"Carcinoid-syndrome: recent advances, current status and controversies","volume":"25","author":"Ito","year":"2018","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"10.1016\/j.ctrv.2025.102907_b0045","doi-asserted-by":"crossref","unstructured":"Modica R, Scandurra C, Maldonato NM, Dolce P, Dipietrangelo GG, Centello R, Di Vito V, Giannetta E, Isidori AM, Lenzi A, Faggiano A, Colao A. Health-related quality of life in patients with neuroendocrine neoplasms: a two-wave longitudinal study. J Endocrinol Invest. 2022 Nov;45(11):2193-2200. doi: 10.1007\/s40618-022-01872-w. Epub 2022 Jul 22. PMID: 35867331; PMCID: PMC9305061.","DOI":"10.1007\/s40618-022-01872-w"},{"key":"10.1016\/j.ctrv.2025.102907_b0050","doi-asserted-by":"crossref","unstructured":"Hofland J, Falconi M, Christ E, Casta\u00f1o JP, Faggiano A, Lamarca A, Perren A, Petrucci S, Prasad V, Ruszniewski P, Thirlwell C, Vullierme MP, Welin S, Bartsch DK. European Neuroendocrine Tumor Society 2023 guidance paper for functioning pancreatic neuroendocrine tumour syndromes. J Neuroendocrinol. 2023 Aug;35(8):e13318. doi: 10.1111\/jne.13318. Epub 2023 Aug 14. PMID: 37578384.","DOI":"10.1111\/jne.13318"},{"key":"10.1016\/j.ctrv.2025.102907_b0055","doi-asserted-by":"crossref","unstructured":"Yanan Cao, Zhibo G,Lin L, Xiuli J, Aijing S, Jie C et al. Nat Commun. 2013:4:2810. doi: 10.1038\/ncomms3810. Whole exome sequencing of insulinoma reveals recurrent T372R mutations in YY1.","DOI":"10.1038\/ncomms3810"},{"key":"10.1016\/j.ctrv.2025.102907_b0060","doi-asserted-by":"crossref","unstructured":"Ito T, Lee L, Jensen RT. Treatment of symptomatic neuroendocrine tumor syndromes: recent advances and controversies. Expert Opin Pharmacother. 2016 Nov;17(16):2191-2205. doi: 10.1080\/14656566.2016.1236916. Epub 2016 Sep 23. PMID: 27635672; PMCID: PMC5545682.","DOI":"10.1080\/14656566.2016.1236916"},{"issue":"6","key":"10.1016\/j.ctrv.2025.102907_b0065","doi-asserted-by":"crossref","first-page":"539","DOI":"10.3390\/ph14060539","article-title":"Carcinoid syndrome and hyperinsulinemic hypoglycemia associated with neuroendocrine neoplasms: a critical review on clinical and pharmacological management","volume":"14","author":"Spada","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"issue":"11","key":"10.1016\/j.ctrv.2025.102907_b0070","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1016\/j.ejca.2013.02.029","article-title":"Rare neuroendocrine tumours: results of the surveillance of rare cancers in Europe project","volume":"49","author":"van der Zwan","year":"2013","journal-title":"Eur J Can"},{"issue":"6","key":"10.1016\/j.ctrv.2025.102907_b0075","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1097\/MPA.0b013e3181ec124e","article-title":"The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems","volume":"39","author":"Klimstra","year":"2010","journal-title":"Pancreas"},{"issue":"10","key":"10.1016\/j.ctrv.2025.102907_b0080","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","article-title":"Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States","volume":"3","author":"Dasari","year":"2017","journal-title":"JAMA Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2025.102907_b0085","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1470-2045(17)30110-9","article-title":"Frequency of carcinoid syndrome at neuroendocrine tumor diagnosis: a population-based study","volume":"18","author":"Halperin","year":"2017","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2025.102907_b0090","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s12020-023-03649-4","article-title":"Epidemiology of gastroenteropancreatic neuroendocrine neoplasms: a review and protocol presentation for bridging tumor registry data with the Italian association for neuroendocrine tumors (Itanet) national database","volume":"84","author":"Panzuto","year":"2024","journal-title":"Endocrine"},{"issue":"35","key":"10.1016\/j.ctrv.2025.102907_b0095","doi-asserted-by":"crossref","first-page":"5890","DOI":"10.3748\/wjg.v27.i35.5890","article-title":"Gastrinoma and Zollinger Ellison syndrome: a roadmap for the management between new and old therapies","volume":"27","author":"Rossi","year":"2021","journal-title":"World J Gastroenterol"},{"issue":"12","key":"10.1016\/j.ctrv.2025.102907_b0100","article-title":"Cardio-metabolic indices and metabolic syndrome as predictors of clinical severity of gastroenteropancreatic neuroendocrine tumors","volume":"18","author":"Barrea","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"4","key":"10.1016\/j.ctrv.2025.102907_b0110","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s40618-022-01983-4","article-title":"Endocrine-disrupting chemicals (EDCs) and cancer: new perspectives on an old relationship","volume":"46","author":"Modica","year":"2023","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.ctrv.2025.102907_b0115","doi-asserted-by":"crossref","unstructured":"Cryer PE, Axelrod L, Grossman AB, Heller SR, Montori VM, Seaquist ER, et al. Endocrine Society. Evaluation and management of adult hypoglycemic disorders: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2009 Mar;94(3):709-28. doi: 10.1210\/jc.2008-1410. Epub 2008 Dec 16. PMID: 19088155.","DOI":"10.1210\/jc.2008-1410"},{"issue":"9","key":"10.1016\/j.ctrv.2025.102907_b0120","first-page":"753","article-title":"Presentation, diagnostic features and glucose handling in a monocentric series of insulinomas","volume":"36","author":"Toaiari","year":"2013","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.ctrv.2025.102907_b0125","doi-asserted-by":"crossref","unstructured":"Vilarrasa N, Bret\u00f3n I, Ballesteros-Pomar M, Lecube A, Goday A, Pellitero S et al. GOSEEN (Grupo de Obesidad de la Sociedad Espa\u00f1ola de Endocrinolog\u00eda y Nutrici\u00f3n). Recommendations for the diagnosis and treatment of hypoglycaemia after bariatric surgery. Endocrinol Diabetes Nutr (Engl Ed). 2022 Nov;69(9):723-731. doi: 10.1016\/j.endien.2021.09.005. Epub 2022 Nov 21. PMID: 36424342.","DOI":"10.1016\/j.endien.2021.09.005"},{"issue":"1","key":"10.1016\/j.ctrv.2025.102907_b0130","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s12020-020-02287-4","article-title":"Diagnosis of Flier's syndrome in a patient with nondiabetic hypoglycemia: a case report and critical appraisal of the literature","volume":"69","author":"Cimmino","year":"2020","journal-title":"Endocrine"},{"key":"10.1016\/j.ctrv.2025.102907_b0135","doi-asserted-by":"crossref","unstructured":"Douillard C, Jannin A, Vantyghem MC. Rare causes of hypoglycemia in adults. Ann Endocrinol (Paris). 2020 Jun;81(2-3):110-117. doi: 10.1016\/j.ando.2020.04.003. Epub 2020 Apr 10. Erratum in: Ann Endocrinol (Paris). 2022 Dec;83(6):479. doi: 10.1016\/j.ando.2022.03.001. PMID: 32409005.","DOI":"10.1016\/j.ando.2022.03.001"},{"issue":"21","key":"10.1016\/j.ctrv.2025.102907_b0140","article-title":"Nesidioblastosis associated with pancreatic heterotopia as a differential diagnosis of hypoglycemia: a literature review and case report","volume":"6","author":"Lopes","year":"2020","journal-title":"Am J Case Rep"},{"key":"10.1016\/j.ctrv.2025.102907_b0145","unstructured":"Song X, Zheng S, Yang G, Xiong G, Cao Z, Feng M et al. Glucagonoma and the glucagonoma syndrome. Oncol Lett. 2018 Mar;15(3):2749-2755. doi: 10.3892\/ol.2017.7703. Epub 2017 Dec 28. PMID: 29435000; PMCID: PMC5778850."},{"key":"10.1016\/j.ctrv.2025.102907_b0170","doi-asserted-by":"crossref","unstructured":"Modica R, La Salvia A, Liccardi A, Cozzolino A, Di Sarno A, Russo F et al. NIKE group. Dyslipidemia, lipid-lowering agents and neuroendocrine neoplasms: new horizons. Endocrine. 2024 Aug;85(2):520-531. doi: 10.1007\/s12020-024-03767-7. Epub 2024 Mar 20. PMID: 38509261; PMCID: PMC11291585.","DOI":"10.1007\/s12020-024-03767-7"},{"issue":"5","key":"10.1016\/j.ctrv.2025.102907_b0175","doi-asserted-by":"crossref","first-page":"R219","DOI":"10.1530\/EJE-17-0295","article-title":"Management of endocrine disease: flushing: current concepts","volume":"177","author":"Huguet","year":"2017","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"10.1016\/j.ctrv.2025.102907_b0180","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s11154-016-9394-8","article-title":"Flushing in (neuro)endocrinology","volume":"17","author":"Hannah-Shmouni","year":"2016","journal-title":"Rev Endocr Metab Disord"},{"key":"10.1016\/j.ctrv.2025.102907_b0185","doi-asserted-by":"crossref","unstructured":"O'Toole D, Grossman A, Gross D, Delle Fave G, Barkmanova J, O'Connor J, et al. Mallorca Consensus Conference participants; European Neuroendocrine Tumor Society. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: biochemical markers. Neuroendocrinology. 2009;90(2):194-202. doi: 10.1159\/000225948. Epub 2009 Aug 28. PMID: 19713711.","DOI":"10.1159\/000225948"},{"issue":"15","key":"10.1016\/j.ctrv.2025.102907_b0190","first-page":"11","article-title":"Does this patient have pheochromocytoma? A systematic review of clinical signs and symptoms","volume":"31","author":"Pourian","year":"2016","journal-title":"J Diabetes Metab Disord"},{"key":"10.1016\/j.ctrv.2025.102907_b0195","doi-asserted-by":"crossref","unstructured":"Freedman RR. Menopausal hot flashes: mechanisms, endocrinology, treatment. J Steroid Biochem Mol Biol. 2014 Jul;142:115-20. doi: 10.1016\/j.jsbmb.2013.08.010. Epub 2013 Sep 4. PMID: 24012626; PMCID: PMC4612529.","DOI":"10.1016\/j.jsbmb.2013.08.010"},{"key":"10.1016\/j.ctrv.2025.102907_b0200","doi-asserted-by":"crossref","unstructured":"Avis NE, Crawford SL, Greendale G, Bromberger JT, Everson-Rose SA, Gold EB et al. Study of Women's Health Across the Nation. Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Intern Med. 2015 Apr;175(4):531-9. doi: 10.1001\/jamainternmed.2014.8063. PMID: 25686030; PMCID: PMC4433164.","DOI":"10.1001\/jamainternmed.2014.8063"},{"key":"10.1016\/j.ctrv.2025.102907_b0205","doi-asserted-by":"crossref","unstructured":"Garje R, Chennamadhavuni A, Mott SL, Chambers IM, Gellhaus P, Zakharia Y et al. Utilization and outcomes of surgical castration in comparison to medical castration in metastatic prostate cancer. Clin Genitourin Cancer. 2020 Apr;18(2):e157-e166. doi: 10.1016\/j.clgc.2019.09.020. Epub 2019 Sep 26. PMID: 31956009; PMCID: PMC7190190.","DOI":"10.1016\/j.clgc.2019.09.020"},{"issue":"8","key":"10.1016\/j.ctrv.2025.102907_b0210","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.3390\/jcm9082468","article-title":"Differential diagnosis and management of Diarrhea in patients with neuroendocrine tumors","volume":"9","author":"Pusceddu","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.ctrv.2025.102907_b0215","doi-asserted-by":"crossref","DOI":"10.1177\/1179551419884058","article-title":"Management of gastrointestinal neuroendocrine tumors","volume":"12","author":"Wang","year":"2019","journal-title":"Clin Med Insights Endocrinol Diabetes"},{"issue":"10","key":"10.1016\/j.ctrv.2025.102907_b0220","first-page":"950","article-title":"Biomarkers in small intestine NETs and carcinoid heart disease: a comprehensive review","volume":"10","author":"Kalligeros","year":"2021","journal-title":"Biology (Basel)"},{"key":"10.1016\/j.ctrv.2025.102907_b0225","doi-asserted-by":"crossref","unstructured":"Naraev BG, Halland M, Halperin DM, Purvis AJ, O\u2019dorisio TM, Halfdanarson TR. Management of Diarrhea in Patients with Carcinoid Syndrome. Pancreas 2019;48:961\u2013972.","DOI":"10.1097\/MPA.0000000000001384"},{"issue":"9","key":"10.1016\/j.ctrv.2025.102907_b0230","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1007\/s10620-017-4695-7","article-title":"Catching the Zebra: clinical pearls and pitfalls for the successful diagnosis of Zollinger-Ellison syndrome","volume":"62","author":"Mendelson","year":"2017","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.ctrv.2025.102907_b0235","unstructured":"Sandhu S, Jialal I. ViPoma. [Updated 2023 Jun 12]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-.Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK507698\/."},{"key":"10.1016\/j.ctrv.2025.102907_b0240","unstructured":"Linee Guida AIOM 2021 (updated 2022). Neoplasie Neuroendocrine."},{"key":"10.1016\/j.ctrv.2025.102907_b0245","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1210\/er.2003-0014","article-title":"The diagnosis and medical management of advanced neuroendocrine tumors","volume":"25","author":"Kaltsas","year":"2004","journal-title":"Endocr Rev"},{"key":"10.1016\/j.ctrv.2025.102907_b0250","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1080\/10408398.2017.1390729","article-title":"on behalf of NIKE Group. The management of neuroendocrine tumours: a nutritional viewpoint","volume":"59","author":"Gallo","year":"2017","journal-title":"Crit Rev Food Sci Nutr"},{"key":"10.1016\/j.ctrv.2025.102907_b0255","doi-asserted-by":"crossref","unstructured":"Grozinsky-Glasberg S, Davar J, Hofland J, Dobson R, Prasad V, Pascher A, Denecke T, Tesselaar MET, Panzuto F, Alb\u00e5ge A, Connolly HM, Obadia JF, Riechelmann R, Toumpanakis C. European Neuroendocrine Tumor Society (ENETS) 2022 Guidance Paper for Carcinoid Syndrome and Carcinoid Heart Disease. J Neuroendocrinol. 2022 Jul;34(7):e13146. doi: 10.1111\/jne.13146. Epub 2022 May 25. PMID: 35613326; PMCID: PMC9539661.","DOI":"10.1111\/jne.13146"},{"key":"10.1016\/j.ctrv.2025.102907_b0260","doi-asserted-by":"crossref","unstructured":"Rubin de Celis Ferrari AC, Glasberg J, Riechelmann RP. Carcinoid syndrome: update on the pathophysiology and treatment. Clinics (Sao Paulo). 2018 Aug 20;73(suppl 1):e490s. doi: 10.6061\/clinics\/2018\/e490s. PMID: 30133565; PMCID: PMC6096975.","DOI":"10.6061\/clinics\/2018\/e490s"},{"key":"10.1016\/j.ctrv.2025.102907_b0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.comppsych.2021.152244","article-title":"Serotoninergic brain dysfunction in neuroendocrine tumor patients: a scoping review","volume":"109","author":"La Salvia","year":"2021","journal-title":"Compr Psychiatry"},{"issue":"16","key":"10.1016\/j.ctrv.2025.102907_b0270","doi-asserted-by":"crossref","first-page":"4065","DOI":"10.3390\/cancers15164065","article-title":"Urinary 5-hydroxyindolacetic acid measurements in patients with neuroendocrine tumor-related carcinoid syndrome: state of art","volume":"15","author":"Rossi","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.ctrv.2025.102907_b0275","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1159\/000493317","article-title":"Evaluation of clinical prognostic factors and further delineation of the effect of mesenteric fibrosis on survival in advanced midgut neuroendocrine tumours","volume":"107","author":"Laskaratos","year":"2018","journal-title":"Neuroendocrinology"},{"issue":"9","key":"10.1016\/j.ctrv.2025.102907_b0280","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.4158\/EP151172.OR","article-title":"ELECT Study Group *. Evaluation of lanreotide depot\/autogel efficacy and safety as a carcinoid syndrome treatment (elect): a randomized, double-blind, placebo-controlled trial","volume":"22","author":"Vinik","year":"2016","journal-title":"Endocr Pract"},{"key":"10.1016\/j.ctrv.2025.102907_b0285","doi-asserted-by":"crossref","unstructured":"Riechelmann RP, Pereira AA, Rego JF, Costa FP. Refractory carcinoid syndrome: a review of treatment options. Ther Adv Med Oncol. 2017 Feb;9(2):127-137. doi: 10.1177\/1758834016675803. Epub 2016 Nov 2. PMID: 28203303; PMCID: PMC5298401.","DOI":"10.1177\/1758834016675803"},{"issue":"9","key":"10.1016\/j.ctrv.2025.102907_b0290","first-page":"3695","article-title":"Health-related quality of life in patients with neuroendocrine tumors: an investigation of treatment type, disease status, and symptom burden","volume":"24","author":"Pearman","year":"2016","journal-title":"Support Care Can"},{"issue":"9","key":"10.1016\/j.ctrv.2025.102907_b0295","doi-asserted-by":"crossref","first-page":"838","DOI":"10.4065\/mcp.2010.0099","article-title":"Paraneoplastic syndromes: an approach to diagnosis and treatment","volume":"85","author":"Pelosof","year":"2010","journal-title":"Mayo Clin Proc"},{"issue":"3","key":"10.1016\/j.ctrv.2025.102907_b0300","doi-asserted-by":"crossref","first-page":"R173","DOI":"10.1677\/ERC-10-0024","article-title":"Paraneoplastic syndromes secondary to neuroendocrine tumours","volume":"17","author":"Kaltsas","year":"2010","journal-title":"Endocr Relat Can"},{"issue":"4","key":"10.1016\/j.ctrv.2025.102907_b0305","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/S0889-8588(05)70370-1","article-title":"Endocrinopathy and ectopic hormones in malignancy","volume":"10","author":"Keffer","year":"1996","journal-title":"Hematol Oncol Clin N Am"},{"issue":"7","key":"10.1016\/j.ctrv.2025.102907_b0310","doi-asserted-by":"crossref","first-page":"499","DOI":"10.7326\/0003-4819-112-7-499","article-title":"Cancer-associated hypercalcemia: morbidity and mortality. Clinical experience in 126 treated patients","volume":"112","author":"Ralston","year":"1990","journal-title":"Ann Intern Med"},{"issue":"4","key":"10.1016\/j.ctrv.2025.102907_b0315","doi-asserted-by":"crossref","first-page":"415","DOI":"10.2174\/092986708783497346","article-title":"Medical treatment of malignancy-associated hypercalcemia","volume":"15","author":"Lumachi","year":"2008","journal-title":"Curr Med Chem"},{"issue":"6","key":"10.1016\/j.ctrv.2025.102907_b0320","doi-asserted-by":"crossref","first-page":"R173","DOI":"10.1530\/ERC-17-0036","article-title":"Paraneoplastic endocrine syndromes","volume":"24","author":"Dimitriadis","year":"2017","journal-title":"Endocr Relat Can"},{"issue":"10","key":"10.1016\/j.ctrv.2025.102907_b0325","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.3390\/jpm12101553","article-title":"What lies behind paraneoplastic hypercalcemia secondary to well-differentiated neuroendocrine neoplasms? A systematic review of the literature","volume":"12","author":"Giannetta","year":"2022","journal-title":"J Pers Med"},{"issue":"5","key":"10.1016\/j.ctrv.2025.102907_b0330","doi-asserted-by":"crossref","first-page":"G9","DOI":"10.1530\/EC-16-0055","article-title":"Society for Endocrinology clinical c. society for endocrinology endocrine emergency guidance: emergency management of acute hypercalcaemia in adult patients","volume":"5","author":"Walsh","year":"2016","journal-title":"Endocr Connect"},{"key":"10.1016\/j.ctrv.2025.102907_b0335","doi-asserted-by":"crossref","unstructured":"El-Hajj Fuleihan G, Clines GA, Hu MI, Marcocci C, Murad MH, Piggott T et al. Treatment of hypercalcemia of malignancy in adults: an endocrine society clinical practice guideline. J Clin Endocrinol Metabol 2023;108(3):507-528. doi: 10.1210\/clinem\/dgac621.","DOI":"10.1210\/clinem\/dgac621"},{"issue":"18","key":"10.1016\/j.ctrv.2025.102907_b0340","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJM199204303261806","article-title":"Management of acute hypercalcemia","volume":"326","author":"Bilezikian","year":"1992","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.ctrv.2025.102907_b0345","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1093\/jnci\/djt225","article-title":"Denosumab for patients with persistent or relapsed hypercalcemia of malignancy despite recent bisphosphonate treatment","volume":"105","author":"Hu","year":"2013","journal-title":"J Natl Can Inst"},{"issue":"5","key":"10.1016\/j.ctrv.2025.102907_b0350","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1590\/2359-3997000000291","article-title":"Use of cinacalcet and sunitinib to treat hypercalcaemia due to a pancreatic neuroendocrine tumor","volume":"61","author":"Valdes-Socin","year":"2017","journal-title":"Arch Endocrinol Metabol"},{"issue":"3","key":"10.1016\/j.ctrv.2025.102907_b0355","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.tem.2019.11.003","article-title":"Endocrinological toxicity secondary to treatment of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs)","volume":"31","author":"Alexandraki","year":"2020","journal-title":"Trends Endocrinol Metab"},{"key":"#cr-split#-10.1016\/j.ctrv.2025.102907_b0360.1","doi-asserted-by":"crossref","unstructured":"Castillo JJ, Vincent M, Justice E. Diagnosis and management of hyponatremia in cancer patients. The Oncologist 2012;17(6):756-765","DOI":"10.1634\/theoncologist.2011-0400"},{"key":"#cr-split#-10.1016\/j.ctrv.2025.102907_b0360.2","doi-asserted-by":"crossref","unstructured":"Howard JD Jr, Deveaux PG. Syndrome of inappropriate antidiuretic hormone associated with rectal small cell neuroendocrine carcinoma: a case report. Journal of surgical case reports. 2017;2017(7):rjx136.","DOI":"10.1093\/jscr\/rjx136"},{"issue":"5","key":"10.1016\/j.ctrv.2025.102907_b0365","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1097\/MPA.0000000000000558","article-title":"A Case of pancreatic small cell neuroendocrine carcinoma associated with SIADH","volume":"45","author":"Pescatori","year":"2016","journal-title":"Pancreas"},{"issue":"20","key":"10.1016\/j.ctrv.2025.102907_b0370","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1056\/NEJMcp066837","article-title":"Clinical practice. The syndrome of inappropriate antidiuresis","volume":"356","author":"Ellison","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2025.102907_b0375","doi-asserted-by":"crossref","unstructured":"Cuesta. Thompson The syndrome of inappropriate antidiuresis (SIAD) Best Pract Res Clin Endocrinol Metab 2016;30:175-87.","DOI":"10.1016\/j.beem.2016.02.009"},{"issue":"20","key":"10.1016\/j.ctrv.2025.102907_b0380","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1056\/NEJMoa065181","article-title":"Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia","volume":"355","author":"Schrier","year":"2006","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ctrv.2025.102907_b0385","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1111\/cen.12943","article-title":"Real-life experience of tolvaptan use in the treatment of severe hyponatraemia due to syndrome of inappropriate antidiuretic hormone secretion","volume":"84","author":"Tzoulis","year":"2016","journal-title":"Clin Endocrinol"},{"issue":"2","key":"10.1016\/j.ctrv.2025.102907_b0390","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.ecl.2018.01.005","article-title":"The ectopic adrenocorticotropic hormone syndrome: rarely easy, always challenging","volume":"47","author":"Hayes","year":"2018","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1016\/j.ctrv.2025.102907_b0395","doi-asserted-by":"crossref","unstructured":"Wijewardene AA, Glastras SJ, Learoyd DL, Robinson BG, Tsang VHM. ACTH-secreting medullary thyroid cancer: a case series. Endocrinology, diabetes & metabolism case reports. 2017;2017; Verma R, Lambert A, Katz HH, Benson SJ. Ectopic ACTH-producing large cell neuroendocrine Pancoast tumour presenting as Horner syndrome. BMJ case reports. 2017.","DOI":"10.1530\/EDM-16-0110"},{"key":"10.1016\/j.ctrv.2025.102907_b0400","article-title":"Ectopic ACTH- and\/or CRH-producing pheochromocytomas","author":"Elliott","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ctrv.2025.102907_b0405","doi-asserted-by":"crossref","DOI":"10.1530\/EDM-19-0002","article-title":"A unique case of ectopic Cushing's syndrome from a thymic neuroendocrine carcinoma","author":"Lawrence","year":"2019","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"issue":"5","key":"10.1016\/j.ctrv.2025.102907_b0410","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s11102-018-0894-2","article-title":"Two types of ectopic Cushing syndrome or a continuum?","volume":"21","author":"Araujo Castro","year":"2018","journal-title":"Pituitary"},{"issue":"3","key":"10.1016\/j.ctrv.2025.102907_b0415","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.thorsurg.2014.05.002","article-title":"Ectopic Cushing and other paraneoplastic syndromes in thoracic neuroendocrine tumors","volume":"24","author":"Ferone","year":"2014","journal-title":"Thorac Surg Clin"},{"key":"10.1016\/j.ctrv.2025.102907_b0420","doi-asserted-by":"crossref","unstructured":"Treatment of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline. Nieman LK, Biller BM, Findling JW, Murad MH, Newell-Price J, Savage MO, Tabarin A; Endocrine Society. J Clin Endocrinol Metab. 2015 Aug;100(8):2807-31.","DOI":"10.1210\/jc.2015-1818"},{"issue":"4","key":"10.1016\/j.ctrv.2025.102907_b0425","doi-asserted-by":"crossref","first-page":"R29","DOI":"10.1530\/EJE-19-0877","article-title":"management of endocrine disease: Cushing's syndrome due to ectopic ACTH secretion: an expert operational opinion","volume":"182","author":"Young","year":"2020","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ctrv.2025.102907_b0430","doi-asserted-by":"crossref","unstructured":"Lebek-Szatanska A, Nowak KM, Zgliczynski W, Baum E, Zylka A, Papierska L. Low-dose etomidate for the management of severe hypercortisolaemia in different clinical scenarios: a case series and review of the literature. Therapeutic advances in endocrinology and metabolism; 2019.","DOI":"10.1530\/endoabs.56.GP15"},{"key":"#cr-split#-10.1016\/j.ctrv.2025.102907_b0435.1","doi-asserted-by":"crossref","unstructured":"Melmed S. Medical progress: Acromegaly. The New England journal of medicine. 2006;355(24):2558-2573","DOI":"10.1056\/NEJMra062453"},{"key":"#cr-split#-10.1016\/j.ctrv.2025.102907_b0435.2","doi-asserted-by":"crossref","unstructured":"Biermasz NR, Smit JW, Pereira AM, Frolich M, Romijn JA, Roelfsema F. Acromegaly caused by growth hormone-releasing hormone-producing tumors: long-term observational studies in three patients. Pituitary. 2007;10(3):237-249.","DOI":"10.1007\/s11102-007-0045-7"},{"issue":"8","key":"10.1016\/j.ctrv.2025.102907_b0440","first-page":"614","article-title":"Medical treatment of gastrointestinal neuroendocrine neoplasms. Hormone and metabolic research, Hormones et metabolisme. 2020","volume":"52","author":"Tsoli","year":"2020","journal-title":"Horm Metab Res"},{"issue":"2","key":"10.1016\/j.ctrv.2025.102907_b0445","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1159\/000443167","article-title":"Vienna consensus conference participants. ENETS Consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site","volume":"103","author":"Pavel","year":"2016","journal-title":"Neuroendocrinology"},{"issue":"2","key":"10.1016\/j.ctrv.2025.102907_b0450","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1159\/000443170","article-title":"Vienna consensus conference participants. ENETS consensus guidelines update for neuroendocrine neoplasms of the jejunum and ileum","volume":"103","author":"Niederle","year":"2016","journal-title":"Neuroendocrinology"},{"issue":"6","key":"10.1016\/j.ctrv.2025.102907_b0455","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1097\/MPA.0000000000000850","article-title":"The North American neuroendocrine tumor society consensus guidelines for surveillance and medical management of midgut neuroendocrine tumors","volume":"46","author":"Strosberg","year":"2017","journal-title":"Pancreas"},{"key":"10.1016\/j.ctrv.2025.102907_b0460","doi-asserted-by":"crossref","unstructured":"Grozinsky-Glasberg S, Davar J, Hofland, Dobson R, Prasad V, Pascher A, Denecke T, Tesselaar M.E.T, Panzuto F, Alb\u00e5ge A, Connolly HM, Obadia JF, Richelman R, Toumpanakis C. European Neuroendocrine Tumor Society (ENETS) 2022 Guidance Paper for Carcinoid Syndrome and Carcinoid Heart Disease. J Neuroendocrinol. 2022 2022 Jul;34(7):e13146. doi: 10.1111\/jne.13146.","DOI":"10.1111\/jne.13146"},{"issue":"3","key":"10.1016\/j.ctrv.2025.102907_b0465","doi-asserted-by":"crossref","DOI":"10.1111\/jne.13060","article-title":"ENETS carcinoid heart disease task force. Synoptic reporting of echocardiography in carcinoid heart disease (ENETS Carcinoid Heart Disease Task Force)","volume":"34","author":"Hofland","year":"2022","journal-title":"J Neuroendocrinol"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737225000295?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737225000295?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T03:01:17Z","timestamp":1763521277000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737225000295"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":90,"alternative-id":["S0305737225000295"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2025.102907","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Functioning neuroendocrine tumors (NET): Minimum requirements for a NET specialist","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2025.102907","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102907"}}